Published in Cancer Med on August 10, 2017
Metastasis to bone: causes, consequences and therapeutic opportunities. Nat Rev Cancer (2002) 12.45
Safety and antitumor activity of recombinant soluble Apo2 ligand. J Clin Invest (1999) 7.69
Directing cancer cells to self-destruct with pro-apoptotic receptor agonists. Nat Rev Drug Discov (2008) 2.95
Ligand-based targeting of apoptosis in cancer: the potential of recombinant human apoptosis ligand 2/Tumor necrosis factor-related apoptosis-inducing ligand (rhApo2L/TRAIL). J Clin Oncol (2008) 2.57
Phase I dose-escalation study of recombinant human Apo2L/TRAIL, a dual proapoptotic receptor agonist, in patients with advanced cancer. J Clin Oncol (2010) 2.43
Randomized Phase II Trial of Gemcitabine Plus TH-302 Versus Gemcitabine in Patients With Advanced Pancreatic Cancer. J Clin Oncol (2014) 2.43
Potent and highly selective hypoxia-activated achiral phosphoramidate mustards as anticancer drugs. J Med Chem (2008) 2.35
Osteosarcoma development and stem cell differentiation. Clin Orthop Relat Res (2008) 2.18
An Fcγ receptor-dependent mechanism drives antibody-mediated target-receptor signaling in cancer cells. Cancer Cell (2011) 2.14
New molecular insights into osteosarcoma targeted therapy. Curr Opin Oncol (2013) 1.97
NCCN Task Force Report: Bone Health in Cancer Care. J Natl Compr Canc Netw (2009) 1.97
Induction of tumor-specific T cell immunity by anti-DR5 antibody therapy. J Exp Med (2004) 1.73
Adjuvant chemotherapy of high-grade osteosarcoma of the extremity. Updated results of the Multi-Institutional Osteosarcoma Study. Clin Orthop Relat Res (1991) 1.56
Molecular mechanisms of tumor-bone interactions in osteolytic metastases. Crit Rev Eukaryot Gene Expr (2000) 1.55
Cripto regulates hematopoietic stem cells as a hypoxic-niche-related factor through cell surface receptor GRP78. Cell Stem Cell (2011) 1.47
A randomized, placebo-controlled phase 2 study of ganitumab (AMG 479) or conatumumab (AMG 655) in combination with gemcitabine in patients with metastatic pancreatic cancer. Ann Oncol (2012) 1.34
Phase 1b study of dulanermin (recombinant human Apo2L/TRAIL) in combination with paclitaxel, carboplatin, and bevacizumab in patients with advanced non-squamous non-small-cell lung cancer. J Clin Oncol (2010) 1.31
Histomorphometric evidence for osteoclast-mediated bone resorption in metastatic breast cancer. Bone (1994) 1.31
Recent advances in osteosarcoma. Curr Opin Pharmacol (2014) 1.24
A Phase 1b/2 trial of mapatumumab in patients with relapsed/refractory non-Hodgkin's lymphoma. Br J Cancer (2010) 1.19
Phase II study of the safety and antitumor activity of the hypoxia-activated prodrug TH-302 in combination with doxorubicin in patients with advanced soft tissue sarcoma. J Clin Oncol (2014) 1.17
Mechanisms of the development of osteoblastic metastases. Cancer (1997) 1.12
Review of the molecular pathogenesis of osteosarcoma. Asian Pac J Cancer Prev (2014) 1.08
Bone health in adult cancer survivorship. J Clin Oncol (2012) 1.03
Apomab, a fully human agonistic antibody to DR5, exhibits potent antitumor activity against primary and metastatic breast cancer. Mol Cancer Ther (2009) 1.00
Osteolysis and cancer. J Clin Invest (2001) 0.99
Death receptor agonist therapies for cancer, which is the right TRAIL? Cytokine Growth Factor Rev (2013) 0.96
Targeting Apo2L/TRAIL receptors by soluble Apo2L/TRAIL. Cancer Lett (2011) 0.96
P-glycoprotein expression: critical determinant in the response to osteosarcoma chemotherapy. J Natl Cancer Inst (1997) 0.94
Molecular basis of the spectrum of skeletal complications of neoplasia. Cancer (2000) 0.93
Apo2L/TRAIL inhibits tumor growth and bone destruction in a murine model of multiple myeloma. Clin Cancer Res (2009) 0.93
Pyruvate sensitizes pancreatic tumors to hypoxia-activated prodrug TH-302. Cancer Metab (2015) 0.90
Hypoxia-activated pro-drug TH-302 exhibits potent tumor suppressive activity and cooperates with chemotherapy against osteosarcoma. Cancer Lett (2014) 0.87
Emerging monoclonal antibodies and related agents for the treatment of chronic lymphocytic leukemia. Future Oncol (2013) 0.80
Therapeutic applications of TRAIL receptor agonists in cancer and beyond. Pharmacol Ther (2015) 0.80
Targeting Tumor Necrosis Factor-Related Apoptosis-Inducing Ligand (TRAIL): A Promising Therapeutic Strategy in Gliomas. Semin Pediatr Neurol (2014) 0.80
Anticancer efficacy of the hypoxia-activated prodrug evofosfamide (TH-302) in osteolytic breast cancer murine models. Cancer Med (2016) 0.79
Targeting cancer-initiating cell drug-resistance: a roadmap to a new-generation of cancer therapies? Drug Discov Today (2011) 0.79
Chemotherapy for osteosarcoma and Ewing's sarcoma. Acta Orthop Scand Suppl (1997) 0.78
Imaging in bone sarcomas. The chemotherapist's point of view. Eur J Radiol (2011) 0.76
The TRAIL receptor agonist drozitumab targets basal B triple-negative breast cancer cells that express vimentin and Axl. Breast Cancer Res Treat (2016) 0.76
Hypoxia-activated pro-drug TH-302 exhibits potent tumor suppressive activity and cooperates with chemotherapy against osteosarcoma. Cancer Lett (2014) 0.87
Anticancer efficacy of the hypoxia-activated prodrug evofosfamide (TH-302) in osteolytic breast cancer murine models. Cancer Med (2016) 0.79
Peroxidase enzymes inhibit osteoclast differentiation and bone resorption. Mol Cell Endocrinol (2016) 0.75